Brief: Vertex Announces Key Advancements Across Kidney Portfolio
25/09/2025 13:28
Sept 25 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES KEY ADVANCEMENTS ACROSS KIDNEY PORTFOLIO VERTEX PHARMACEUTICALS INC: FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR POVETACICEPT IN IGA NEPHROPATHY VERTEX PHARMACEUTICALS INC - ON TRACK TO FILE FOR ACCELERATED APPROVAL IN U.S. IN H1 2026 Source text: ID:nBw9fmr9na Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31